Inhibrx To Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

Event to be webcast live on Monday, May 16, 2022 at 1:30 p.m. PT SAN DIEGO , May 12, 2022 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced that it will host a live…

Click here to view original post